Skip to main content
. 2019 Apr 18;10:123. doi: 10.1186/s13287-019-1221-1

Fig. 1.

Fig. 1

IL-33 administration improves survival of mice after TBI. a Survival curves of C57BL/6 mice that were irradiated with 600-cGy TBI followed by daily IL-33 or PBS treatments for 7 days. Data are pooled from three experiments, n = 6 mice per group per experiment. *P < 0.05 compared to untreated controls. b Survival rate of untreated ST2−/− and WT mice was irradiated with 600-cGy. Data are pooled from three experiments, n = 6 mice per group per experiment. *P < 0.05 compared to ST2−/− controls. c sST2 and IL-33 concentration in the bone marrow serum of WT and ST2−/− mice before irradiation (Nonirrad) and at 7 days after 600-cGy irradiation. Data are mean ± SEM (n = 6 in each group). *P < 0.05 compared to nonirradiated controls. d Representative ST2 surface expression on bone marrow Lin− cells and KSL cells from C57BL/6 mice before irradiation and at 6 h after 600-cGy irradiation. The numbers shown indicate the percentage of ST2 surface expression on the indicated cell population. e Survival rate of ST2−/− and WT mice was irradiated with 600-cGy and treated with IL-33 as in a